The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: Results of a prospective, multicenter, randomized, controlled trial
Abstract
OBJECTIVE: To evaluate the safety and efficacy of E5, a murine, monoclonal antibody directed against endotoxin, in the treatment of patients with Gram-negative sepsis. DESIGN: A multicenter, randomized, double-blind, placebo-controlled trial. SETTING: Fifty-three hospitals across the United States, including university medical centers, Veterans Affairs Medical Centers, and community hospitals. PATIENTS: 847 patients were randomized into this study. Enrolled patients met criteria for three conditions: a) known or suspected Gram-negative infection; b) clinical evidence of sepsis; and c) signs of end-organ dysfunction. Patients with refractory shock were excluded from the study. INTERVENTIONS: Two doses of E5 (2 mg/kg/day by intravenous infusion 24 hrs apart), or placebo that was identical in appearance were administered. In addition, all patients received standard supportive therapy and broad-spectrum antibiotics. MEASUREMENTS AND MAIN RESULTS: The primary end point was mortality over 30 days. Secondary outcome measures included the resolution and prevention of organ failure in the same two populations. Additionally, the safety of E5 was evaluated. There was no significant improvement in survival over 30 days among patients with Gram-negative sepsis who received E5 compared with those patients who received placebo (n = 530; p = .21). In addition, E5 did not improve survival for patients with Gram-negative sepsis and organ failure (n = 139; p = .3). However, a significantly greater percentage of patients with Gram-negative sepsis experienced resolution of major organ failure if they received E5, compared with those patients who received placebo (n = 139; 48% E5 vs. 25% placebo; p = .005). This result extended to all patients who entered the study with one or more major organ failures, regardless of the etiology of the infection (n = 225; 41% E5 vs. 27% placebo; p = .024). E5 also provided protection against the development of some organ failures, but significant prevention was only observed for adult respiratory distress syndrome (p = .007) and central nervous system dysfunction (p = .050). Hypersensitivity reactions attributable to E5 occurred in 2.6% of patients. An asymptomatic antibody response occurred in 44% of the E5-treated patients and in 12% of the patients who received placebo. CONCLUSIONS: In this study, E5 did not reduce mortality in nonshock patients with Gram-negative sepsis whether or not those patients also had organ failure. However, E5 did result in greater resolution of organ failure in patients with Gram-negative sepsis. This benefit extended to those patients with suspected Gram-negative etiology. This finding is important because patients with suspected Gram-negative sepsis and organ failure can be identified without waiting for culture results. In addition, E5 resulted in the prevention of adult respiratory distress syndrome and central nervous system organ failure. However, more studies are needed to determine if this result can be extended to organ failure in general. E5 is safe as a treatment for patients with Gram-negative sepsis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ziegler, E. J., Fisher, C. J., Sprung, C. L., Straube, R. C., Sadoff, J. C., Foulke, G. E., Wortel, C. H., Fink, M. P., Dellinger, R. P., Teng, N. N. H., et al. (1991) · New England Journal of Medicine · doi:10.1056/nejm199102143240701 · Cited by 1,611
Bone, R. C., Fisher, C. J., Clemmer, T. P., Slotman, G. J., Metz, C. A., Balk, R. A., & The Methylprednisolone Severe Sepsis Study Group (1987) · New England Journal of Medicine · doi:10.1056/nejm198709103171101 · Cited by 1,440
Self-citationBone, R. C. (1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-115-6-457 · Cited by 1,368
Self-citationENDOTOXINS AND DISEASE MECHANISMS
Morrison, D. C., & Ryan, J. L. (1987) · Annual Review of Medicine · doi:10.1146/annurev.me.38.020187.002221 · Cited by 1,103
Greenman, R. L. (1991) · JAMA · doi:10.1001/jama.266.8.1097 · Cited by 752
Endotoxemia in Human Septic Shock
Danner, R. L., Elin, R. J., Hosseini, J. M., Wesley, R. A., Reilly, J. M., & Parillo, J. E. (1991) · Chest · doi:10.1378/chest.99.1.169 · Cited by 656
McCloskey, R. V., Straube, R. C., Sanders, C., Smith, S. M., Smith, C. R., & and CHESS Trial Study Group. (1994) · Annals of Internal Medicine · doi:10.7326/0003-4819-121-1-199407010-00001 · Cited by 495
Type-Specific and Cross-Reactive Antibodies in Gram-Negative Bacteremia
McCabe, W. R., Kreger, B. E., & Johns, M. (1972) · New England Journal of Medicine · doi:10.1056/nejm197208102870601 · Cited by 210
Serial Quantitation of Endotoxemia and Bacteremia During Therapy for Gram-Negative Bacterial Sepsis
Shenep, J. L., Flynn, P. M., Barrett, F. F., Stidham, G. L., & Westenkirchner, D. F. (1988) · Journal of Infectious Diseases · doi:10.1093/infdis/157.3.565 · Cited by 169
Cited by
Novel strategies for the treatment of sepsis
Riedemann, N. C., Guo, R.-F., & Ward, P. A. (2003) · Nature Medicine · doi:10.1038/nm0503-517 · Cited by 773
Garnacho-Montero, J., Garcia-Garmendia, J. L., Barrero-Almodovar, A., Jimenez-Jimenez, F. J., Perez-Paredes, C., & Ortiz-Leyba, C. (2003) · Critical Care Medicine · doi:10.1097/01.ccm.0000098031.24329.10 · Cited by 718
Postinjury Multiple Organ Failure: A Bimodal Phenomenon
Moore, F. A., Sauaia, A., Moore, E. E., Haenel, J. B., Burch, J. M., & Lezotte, D. C. (1996) · The Journal of Trauma: Injury, Infection, and Critical Care · doi:10.1097/00005373-199604000-00001 · Cited by 491
Systemic inflammatory response syndrome
Davies, M. G., & Hagen, P.-O. (1997) · Journal of British Surgery · doi:10.1002/bjs.1800840707 · Cited by 456
Sanlioglu, S., Williams, C. M., Samavati, L., Butler, N. S., Wang, G., McCray, P. B., Ritchie, T. C., Hunninghake, G. W., Zandi, E., & Engelhardt, J. F. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m102061200 · Cited by 395
Metadata
- Authors
- Bone, R. C., Balk, R. A., Fein, A. M., Perl, T. M., Wenzel, R. P., Reines, H. D., Quenzer, R. W., Iberti, T. J., Macintyre, N., & Schein, R. M. H.
- Venue
- Critical Care Medicine
- Published
- 1995-06
- Volume
- 23
- Issue
- 6
- Pages
- 994-1006
- ISSN
- 0090-3493 (ISSN-L)
- OpenAlex
- W2055289119
- Cited by
- 350
- References
- 13
- FWCI
- 26.82
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: Results of a prospective, multicenter, randomized, controlled trial. https://app.cochat.ai/papers/10.1097/00003246-199506000-00003
- The paper
- Bone, R. C., Balk, R. A., Fein, A. M., Perl, T. M., Wenzel, R. P., Reines, H. D., Quenzer, R. W., Iberti, T. J., Macintyre, N., & Schein, R. M. H. (1995). A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: Results of a prospective, multicenter, randomized, controlled trial. Critical Care Medicine. https://doi.org/10.1097/00003246-199506000-00003
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.